Study of Safety and Efficacy of Eltrombopag Maintainance Therapy in Patients After an Induction Treatment with Eltrombopag 50 mg Orally Once Daily.

Trial Profile

Study of Safety and Efficacy of Eltrombopag Maintainance Therapy in Patients After an Induction Treatment with Eltrombopag 50 mg Orally Once Daily.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 May 2015

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top